KiloBaser

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

KiloBaser - overview

Established

2013

Location

Graz, -, Austria

Primary Industry

Medical Devices & Equipment

About

KiloBaser is an innovative company focused on developing and manufacturing microfluidic chip and cartridge-based synthesizers for on-demand DNA and RNA production, catering to the needs of research institutions and laboratories. Founded in 2013 in Graz, Austria, KiloBaser specializes in synthesizing custom nucleic acids through its advanced technology. The company was established by Bernhard Tittelbach and Martin Jost, and is currently led by CEO Alexander Murer. KiloBaser has completed 4 deals, with the most recent funding round occurring on July 15, 2022.


Kilobaser specializes in the development and manufacturing of the world’s first microfluidic chip and cartridge-based synthesizer for DNA and RNA, enabling the on-demand production of custom nucleic acids. The Kilobaser synthesizer offers a fast, affordable, and independent solution to researchers and laboratories needing to synthesize custom DNA and RNA oligos, probes, and more. This technology eliminates complex ordering processes, long delivery times, and high modification costs, allowing end-users to produce nucleic acids efficiently within their labs. Its clientele includes academic institutions, biotechnology firms, and research organizations across Europe, North America, and South America, with noted installations and user satisfaction in Brazil and other markets.


Kilobaser's revenue model centers on the sales of its flagship synthesizer, alongside associated cartridges and microfluidic chips required for DNA and RNA synthesis. Transactions generally occur through direct sales to research institutions and life sciences companies, establishing a B2B framework for their offerings. Clients purchase equipment and consumables as needed, ensuring a continuous revenue stream as customers maintain and replenish supplies. The company also engages in live demonstrations to showcase the synthesizer's capabilities, fostering customer engagement and loyalty.


Following the Seed funding round on July 15, 2022, in which KiloBaser raised an undisclosed amount from returning investor SOSV, the company plans to utilize these funds for developing new products aimed at enhancing synthesizer capabilities. KiloBaser is also targeting expansion into new markets, particularly in Asia and Africa, with plans to establish a presence by the end of 2023. This strategic approach is designed to broaden its market reach and increase its customer base.


Current Investors

SOSV, IndieBio

Primary Industry

Medical Devices & Equipment

Sub Industries

Medical Devices & Equipment

Website

www.kilobaser.com

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

KiloBaser - employee data

Blurred Background

Want to see Employee Count?

Request a demo for full access to this profile.

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.